US FDA “Enriches” Trial Guidance With Recent Examples
Executive Summary
Illustrating that principles articulated in 2012 draft are being broadly accepted at FDA, final guidance on enrichment strategies for clinical trials adds new examples from across the agency’s drug review divisions.